Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329797 · ClinicalTrials.gov registry record · Phase 3
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 109
- Enrollment target
NCT00329797 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 109 participants.
The verdict
NCT00329797, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 109 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with locally advanced nonmetastatic prostate cancer undergoing radiation therapy and hormone therapy.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- RADIATION radiation therapy
- DIETARY_SUPPLEMENT Calcium
- DIETARY_SUPPLEMENT Zoledronic acid
- DRUG LHRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2006-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329797
The ClinicalTrials.gov registry entry for NCT00329797 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vitamin D is the first listed.
NCT00329797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329797 about?
NCT00329797 is a clinical study titled "Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy". RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in preventing osteoporosis and bone fractures in patients with prostate cancer. ...
What is the current status of trial NCT00329797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 109 participants. The study started on 2006-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00329797?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), radiation therapy (RADIATION), Calcium (DIETARY_SUPPLEMENT), Zoledronic acid (DIETARY_SUPPLEMENT), LHRH (DRUG).
Who is sponsoring clinical trial NCT00329797?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.